LX
Li, Xiangyu
25 papers · 533 citations · 2021–2025
Publications
25
Citations
533
Years
5
Publications
| Title | Year | Type | Citations |
|---|---|---|---|
|
The Human Pathology Atlas for deciphering the prognostic features of human cancers
|
2025 | Article | 6 |
|
Multi-omics characterization of improved cognitive functions in Parkinson's disease patients after the combined metabolic activator treatment: a randomized, double-blinded, placebo-controlled phase II trial
|
2025 | Article | 2 |
|
Identification of <i>SPP1</i><SUP>+</SUP> macrophages as an immune suppressor in hepatocellular carcinoma using single-cell and bulk transcriptomics
|
2024 | Article | 7 |
|
Multi-omics analysis reveals the key factors involved in the severity of the Alzheimer's disease
|
2024 | Article | 26 |
|
Discovery of a Therapeutic Agent for Glioblastoma Using a Systems Biology-Based Drug Repositioning Approach
|
2024 | Article | 3 |
|
Discovery of therapeutic agents targeting PKLR for NAFLD using drug repositioning ( vol 83 , 104214 , 2022)
|
2024 | Correction | 0 |
|
Combined metabolic activators improve metabolic functions in the animal models of neurodegenerative diseases (Retraction of Vol 314, art no 121325, 2023)
|
2024 | Retraction | 0 |
|
Combined metabolic activators improve metabolic functions in the animal models of neurodegenerative diseases
|
2023 | Article | 6 |
|
Open MoA: revealing the mechanism of action (MoA) based on network topology and hierarchy
|
2023 | Article | 5 |
|
Systematic transcriptional analysis of human cell lines for gene expression landscape and tumor representation
|
2023 | Article | 81 |
|
The acute effect of different NAD plus precursors included in the combined metabolic activators
|
2023 | Article | 17 |
|
Longitudinal metabolomics analysis reveals the acute effect of cysteine and NAC included in the combined metabolic activators
|
2023 | Article | 5 |
|
Drug repositioning targeting glutaminase reveals drug candidates for the treatment of Alzheimer's disease patients
|
2023 | Article | 11 |
|
Combined metabolic activators improve cognitive functions in Alzheimer's disease patients: a randomised, double-blinded, placebo-controlled phase-II trial
|
2023 | Article | 60 |
|
Discovery of therapeutic agents targeting <i>PKLR </i>for <i>NAFLD </i>using drug repositioning
|
2022 | Article | 22 |
|
Prediction of drug candidates for clear cell renal cell carcinoma using a systems biology-based drug repositioning approach
|
2022 | Article | 25 |
|
A Gene Co-Expression Network-Based Drug Repositioning Approach Identifies Candidates for Treatment of Hepatocellular Carcinoma
|
2022 | Article | 17 |
|
Multiomics Analysis Reveals the Impact of Microbiota on Host Metabolism in Hepatic Steatosis
|
2022 | Article | 64 |
|
Systems Biology Approaches to Decipher the Underlying Molecular Mechanisms of Glioblastoma Multiforme
|
2021 | Review | 11 |
|
A network-based approach reveals the dysregulated transcriptional regulation in non-alcoholic liver disease
|
2021 | Article | 23 |
|
Revealing the Molecular Mechanisms of Alzheimer's Disease Based on Network Analysis
|
2021 | Article | 19 |
|
Stratification of patients with clear cell renal cell carcinoma to facilitate drug repositioning
|
2021 | Article | 14 |
|
iNetModels 2.0: an interactive visualization and database of multi-omics data
|
2021 | Article | 32 |
|
Combined Metabolic Activators Accelerates Recovery in Mild-to-Moderate COVID-19
|
2021 | Article | 64 |
|
Discovery of Functional Alternatively Spliced <i>PKM</i> Transcripts in Human Cancers
|
2021 | Article | 13 |